These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8638626)

  • 21. Comparative study of the differential white blood cell count using three automated analyzers: Coulter STKS, Sysmex NE 8000 and Technicon H-1.
    Lesesve JF; Lacombe F; Boisseau MR; Bernard P
    Ann Biol Clin (Paris); 1994; 52(4):295-7. PubMed ID: 7802355
    [No Abstract]   [Full Text] [Related]  

  • 22. Red cell osmotic fragility studies in hemoglobin C-beta thalassemia: osmotically resistant microspherocytes.
    Sears DA; Udden MM; Johnston MD
    Clin Lab Haematol; 2003 Dec; 25(6):367-72. PubMed ID: 14641140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypotonic unmasking of erythrocyte receptor sites.
    Geyer G; Linss W; Mönch E; Feuerstein H
    Exp Pathol (Jena); 1979; 17(7-8):434-8. PubMed ID: 510454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane characteristics and osmotic fragility of red cells, fractionated with anglehead centrifugation and counterflow centrifugation.
    van der Vegt SG; Ruben AM; Werre JM; de Gier J; Staal GE
    Br J Haematol; 1985 Nov; 61(3):405-13. PubMed ID: 4063204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudoleucocytosis due to incomplete erythrocyte lysis.
    Mellors I; McArdle P; Bell D
    Clin Lab Haematol; 1995 Dec; 17(4):347-8. PubMed ID: 8697731
    [No Abstract]   [Full Text] [Related]  

  • 26. Association between myeloid malignancies and acquired deficit in protein 4.1R: a retrospective analysis of six patients.
    Alanio-Bréchot C; Schischmanoff PO; Fénéant-Thibault M; Cynober T; Tchernia G; Delaunay J; Garçon L
    Am J Hematol; 2008 Apr; 83(4):275-8. PubMed ID: 17994571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane perturbations of erythrocyte ghosts by spectrin release.
    Yamaguchi T; Ozaki S; Shimomura T; Terada S
    J Biochem; 2007 May; 141(5):747-54. PubMed ID: 17387121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult onset cyclic hematopoiesis in a patient with myelodysplastic syndrome.
    Abe Y; Hirase N; Muta K; Okada Y; Kimura T; Umemura T; Nishimura J; Nawata H
    Int J Hematol; 2000 Jan; 71(1):40-5. PubMed ID: 10729992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
    Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
    Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete analytical and diagnostic performances of the Abbott Cell Dyn 3500.
    Sanzari M; De Toni S; D'Osualdo A; Rossetti M; Floriani F; Plebani M
    Panminerva Med; 1998 Jun; 40(2):116-25. PubMed ID: 9689832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relation between types of erythrocyte membrane defects and the clinical picture in hereditary spherocytosis].
    Brabec V; Palek J; Petrtýlová K; Cermák J; Jarolím P
    Vnitr Lek; 1997 Feb; 43(2):91-4. PubMed ID: 9245075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the automated leucocyte count and differential from the Cell-Dyn 3500 in sickle cell disease.
    Joyner RE; Brooks MJ
    Clin Lab Haematol; 1995 Dec; 17(4):329-33. PubMed ID: 8697728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drop in Coulter S Plus-IV white cell count.
    Campbell K
    Med Lab Sci; 1988 Jul; 45(3):292-3. PubMed ID: 3210938
    [No Abstract]   [Full Text] [Related]  

  • 34. Measurement of the membrane elasticity of red blood cell with osmotic pressure by optical tweezers.
    Wu J; Li Y; Lu D; Liu Z; Cheng Z; He L
    Cryo Letters; 2009; 30(2):89-95. PubMed ID: 19448857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes.
    Saigo K; Takenokuchi M; Imai J; Numata K; Isono S; Zenibayashi M; Tanioka H; Yoshioka T; Nishizawa A; Takada M; Nomura T; Kubota Y
    Lab Hematol; 2009; 15(2):13-6. PubMed ID: 19561008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osmotic effects on feline spermatozoa from normospermic versus teratospermic donors.
    Pukazhenthi B; Noiles E; Pelican K; Donoghue A; Wildt D; Howard J
    Cryobiology; 2000 Mar; 40(2):139-50. PubMed ID: 10788313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Incubated osmotic fragility test does not exclude red blood cell membrane disorders! About a case of hereditary elliptocytosis].
    Perrin J; Marchand-Arvier M; Latger-Cannard V; Vigneron C; Lecompte T
    Ann Biol Clin (Paris); 2006; 64(5):491-5. PubMed ID: 17040882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
    Stasi R; Amadori S
    Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of toluene on erythrocyte membrane stability under in vivo and in vitro conditions with assessment of oxidant/antioxidant status.
    Karabulut I; Balkanci ZD; Pehlivanoglu B; Erdem A; Fadillioglu E
    Toxicol Ind Health; 2009 Sep; 25(8):545-50. PubMed ID: 19825861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.